Meet Icosagen at PEGS Boston May 1-5
Icosagen will be attending the 13th annual PEGS summit held in Boston on May 1-5th, 2017. Come visit us at our booth, #217, and we will be more than happy to accommodate you with both information and insight to our protein and antibody production capabilities.
Read more ›
Icosagen identified several high-risk HPV inhibitors and drug targets with a novel high-throughput screening assay
Genetically engineered HPV genomes enable identification of potential drug
targets and candidates
Scientists have used
genetic engineering techniques to develop a new system that could aid
identification of potential drug targets and treatments for human
papillomavirus (HPV) infection, according to a PLOS Pathogens study.
Read more ›
Meet us at PEPTalk 2017
Icosagen will be attending the 16th annual PepTalk conference held in San Diego on January 9-13th, 2017. Come visit us at our booth, #305, and we will be more than happy to accommodate you with both information and insight to our protein and antibody production capabilities.Our CSO, Meelis Kadaja, will be presenting about: “A Stable
Episomal Expression System to Streamline Antibody Production” on Jan 12 at 3:05pm in the Antibody Therapeutics track.
Read more ›
Icosagen AS donates to SA University of Tartu Clinic's Children foundation
SA University of Tartu Clinic in partnership with Club Tartu Marathon started in 2013 a charity sport event "Heateo jooks". SynLab, Sirowa, Nutri Kaubanduse, Icosagen AS and Uus Apteek all collectively donate 5€ for every attendee to support children with joint disease and weight problems. The run is held at 6th of may and donations are gathered for 3 year old Cassandra with Epidermolysis bullosa (EB).
Read more about the eventRead more at Children foundation (in estonian)
Read more ›
Icosagen developed anti-human BNDF antibody clone 3C11 played prominent role in Neuroscience and JBC publications.
In March, 2016 two research groups published their results in
Neuroscience and JBC using Icosagen-developed
anti-human BDNF antibody.
Read more ›
Press release: Icosagen Cell Factory was awarded EUR 1.2 million
HybriFree recombinant antibody development article is published
Icosagen AS has incorporated a US subsidiary – Icosagen Technologies, Inc.
The Icosagen Cell Factory OÜ team is looking for a MARKETING SPECIALIST
QMCF Technology to be presented at the CHI's 14th Annual PepTalk conference in San Diego, California
Icosagen Cell Factory was titled the Best Entrepreneur of 2013
Icosagen Cell Factory presentation at Cell Line Development Conference